Genome :: Consortium Publishes Phase II Map of Human Genetic Variation

The International HapMap Consortium today published analyses of its second-generation map of human genetic variation, which contains three times more markers than the initial version unveiled in 2005. In two papers in the journal Nature, the consortium describes how the higher resolution map offers greater power to detect genetic variants involved in common diseases, explore the structure of human genetic variation and learn how environmental factors, such as infectious agents, have shaped the human genome.

Breast Cancer :: AACR, BCRF award inaugural grants in translational breast cancer research

Through the generous support of the Breast Cancer Research Foundation (BCRF), the American Association for Cancer Research (AACR) is pleased to announce the inaugural recipients of the 2007 BCRF-AACR Grants in Translational Breast Cancer Research. These grants provide direct support for innovative breast cancer research projects designed to accelerate the discovery, development, and application of new ways to treat breast cancer, or for preclinical research with direct therapeutic implications.

Ultrasound :: Transcutaneous cervical esophageal ultrasound can not substitute for 24-h pH monitoring or manometry

Gastroesophageal reflux arises from increased exposure and/or sensitivity of the esophageal mucosa to gastric contents, and affects 5-40 percent of the population. Esophageal ultrasound studies in GER have mainly focused on the evaluation of the gastroesophageal junction and esophageal motility performed by transabdominal or endoluminal routes. Visualizing refluxate in transcutaneous cervical esophageal ultrasound was found to be useful as a pre-diagnostic tool for estimating GER and/or manometric pathology in 71.1 percent of adults.

Colorectal Cancer :: Interleukin-8, key marker for colorectal cancer treatment

Colorectal cancer (CRC) is currently one of the three most frequent malignancies in Western industrial nations. Although the 5-year survival rate for patients with early stage and local CRC approaches nearly 90%, survival is dramatically decreased by local recurrence and the development of distant metastases that primarily affect the liver, which are the predominant cause of CRC-related mortality.